Spotlight on Internal Medicine

Credits: 0.50 CME / CE
Research-based Clinical Strategies to Prevent and Address Adolescent Substance Use and Prescription Medication Misuse—Being Part of the Solution Part 2
Postgraduate Institute for Medicine

Research-based Clinical Strategies to Prevent and Address Adolescent Substance Use and Prescription Medication Misuse—Being Part of the Solution Part 2

Start

Activity Details

Free
AAFP, ACCME, ANCC, ADA

0.5 Credit

Released: June 29, 2017

Expires: June 27, 2019

30 minutes

No registration required

Target Audience

This activity had been designed to meet the educational needs of clinicians including, physicians, physician assistants, nurse practitioners, nurses, and dentists/oral maxillofacial surgeons, involved in the care of adolescent patients.

Learning Objectives

  • Discuss strategies to address substance use and prescription drug misuse in adolescent patients based on their level of use
  • Summarize when and how to follow up with adolescent patients who use substances or misuse prescription drugs

Activity Description

Videos from your peers enhance this course, which aims to help you navigate confidentiality and confidence in having effective discussions with your teen patients about their substance use. Features tips and talking points for patients at all risk levels, and considerations prescription drug misuse. This course was developed by a Coalition Healthcare Organizations and Providers to help clinicians identify, prevent, and address substance use and prescription medication misuse in their adolescent patients.

Instruction for Claiming Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.

Education Coalition

This activity was developed by an education Coalition of experts and medical professional organization representatives. The Coalition comprises the following organizations and experts:

Type of Reviewer:
Organization/Expert Consultant
Reviewer Name
California Academy of Family Physicians (CAFP) Cynthia Kear, Senior Vice President
American Society of Addiction Medicine (ASAM) Jennifer Butchart, Education Coordinator
Penny Mills, Executive Vice President / CEO
Arlene Deverman, VP Professional Development
American Osteopathic Association (AOA)

Stephanie Townsell, Director, Public Health
Marla Kushner, DO

American Association of Nurse Practitioners (AANP) Anne Norman, DNP, APRN, FNP-C, FAANP Vice President of Education and Accreditation
American Academy of Pediatrics (AAP) Renee Jarrett, Manager, Mental Health and Foster Care Initiatives
Div of Developmental Pediatrics and Preventive Services
American Academy of Physician Assistants (AAPA) Daniel Pace, Vice President, Education
Marie-Michele Leger, MPH, PA-C, Director, Clinical Education
Sara Evans, PMP, Project Manager, Quality Improvement Initiatives
American Association of Oral and Maxillofacial Surgeons (AAOMS) Vincent DiFabio, DDS
Consultant Samantha Mattiucci, PharmD, Director of Medical Education
Consultant Jan Schultz, BSN, MSN, RN, CCMEP, Director of Education Outcomes and Accreditation Services
Consultant Dan Alford, MD, Associate Professor of Medicine, Assistant Dean and Program Director of the Addiction Medicine Residency program at Boston University School of Medicine
Consultant Sharon Levy, MD, MPH, FAAP, Director, Adolescent Substance Abuse Program (ASAP) Assistant Professor in Pediatrics, Boston Children's Hospital
Consultant Jeff Baxter, MD, Assistant Professor
Department of Family Medicine and Community Health, University of Massachusetts Medical School
Consultant Marc Fishman, MD
Consultant Carol Havens, MD

Conflict of Interest Policy/ Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The Education Coalition members reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Marc Fishman, MD discloses the following: Consulting Fees: US World Meds; Contracted Research: Media Rez, US World Meds; Ownership Interest: Maryland Treatment Centers

The following Education Coalition members have nothing to disclose: Cynthia Kear, Jennifer Butchart, Penny Mills, Arlene Deverman, Stephanie Townsell, Marla Kushner, Anne Norman, Renee Jarrett, Daniel Pace, Marie-Michele Leger, Sara Evans, Vincent DiFabio, Jan Schultz, Dan Alford, Sharon Levy, Jeff Baxter, Marc Fishman, and Carol Havens

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following National Institute on Drug Abuse planners and managers, Elisabeth Davis; Carol Krause; Josie Anderson; Jack Stein, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

 The following JBS International, Inc. planners and managers, Candace Baker; Susan Hayashi; Laura Nolan; Bethel Arya; and Veronica Junghahn, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and the National Institute for Drug Abuse. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/30/2017. Term of approval is for one year from this date.

This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.00 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.

Nursing Continuing Education

Credit Designation
This educational activity for 0.5 contact hour is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Accreditation Council for Pharmacy EducationPostgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


American Dental Association CERP Recognition

This continuing education activity has been planned and implemented in accordance with the standards of the ADA Continuing Education Recognition Program (ADA CERP) through joint sponsorship efforts between Postgraduate Institute for Medicine and the National Institute for Drug Abuse.

Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry.

Postgraduate Institute for Medicine designates this activity for 0.5 continuing education credit.

Statement of Commercial Support

There is no commercial funding for this activity.

Media

Internet activity

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware / Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Internal Medicine Presentations

0.75 CME / CNE
Purdue University
The Advances in Monoclonal Antibody Therapeutics to Improve Outcomes in Patients with Psoriatic Arthritis and Ankylosing Spondylitis

The Advances in Monoclonal Antibody Therapeutics to Improve Outcomes in Patients with Psoriatic Arthritis and Ankylosing Spondylitis

Start

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit
0.75 CNE Contact Hour
Released: December 10, 2018
Expires: February 24, 2020
45 minutes to complete

Co-provided By

Target Audience

Rheumatologists, primary care physicians, internists, nurse practitioners, nurses, physician assistants, and other healthcare professionals involved in the management of patients with psoriatic arthritis and ankylosing spondylitis.

Learning Objectives

  1. Understand the immunopathology of PsA and AS, as well as early and accurate diagnosing, and disease monitoring
  2. Analyze clinical trial data of current and emerging therapeutic options for the management of PsA and AS
  3. Implement effective and safe treatment plans to improve outcomes in patients with PsA and AS

Activity Description

This CME/CNE activity is derived from content presented at the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) Annual Meeting in Dallas, Texas. The expert faculty, Dr. Alvin F. Wells, will review the characteristics of both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to ensure accurate detection and early diagnosis. Recent guidelines for the treatment and management of PsA and AS patients will be analyzed, along with approved and emerging therapeutic options and their clinical relevance. Dr. Wells will relay best practices for switching therapies and managing the adverse events associated with approved therapies utilizing the interprofessional team. At the conclusion of this activity, clinicians will become better acquainted with optimal treatment strategies to improve their care of psoriatic arthritis and ankylosing spondylitis patients.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with psoriatic arthritis and ankylosing spondylitis.

Agenda

  1. Psoriatic Arthritis and Ankylosing Spondylitis Update: Immunopathology, Accurate Diagnosing and Disease Monitoring
  2. Clinical Analysis of Current and Emerging Therapeutic Options for PsA and AS
  3. Implementing Safe and Effective Treatment Strategies to Improve Outcomes in Patients

Faculty

Alvin F. Wells, MD, PhD
Alvin F. Wells, MD, PhD
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Assistant Professor, Duke University Medical Center
Director, Rheumatology and Immunotherapy Center
Assistant Clinical Professor, Marquette University
Milwaukee, Wisconsin


Disclosures of Conflict of Interest

All faculty AND staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, reviewers, Purdue and AcademicCME staff have nothing to disclose.

Alvin F. Wells, MD, PhD

Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB. Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and AcademicCME, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This program has been approved for 0.75 contact hour.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity is supported by independent educational grants from Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME; Purdue University College of Pharmacy; Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

1.00 CME
Vindico
Chronic Idiopathic Urticaria: Improving Treatment, With a Focus on Patient Outcomes

Chronic Idiopathic Urticaria: Improving Treatment, With a Focus on Patient Outcomes

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: April 18, 2019
Expires: April 17, 2020
1 hour to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists and other health care professionals involved in the treatment of patients with chronic idiopathic urticaria (CIU).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the impact of chronic idiopathic urticaria (CIU) on quality of life, including sleep, psychological functioning, work and activity.
  • Compare the strengths and limitations of current guideline approaches to the management of CIU.
  • Select treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Description

Urticaria, a common skin condition characterized by transient pruritic wheals, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration over 6 weeks may be diagnosed as having chronic idiopathic urticaria (CIU). CIU negatively impacts physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease awaiting bypass surgery. A US practice guideline issued in 2014 and an updated international guideline issued in 2018 are available to guide diagnosis and treatment of urticaria. Although the recommendations in these guidelines largely overlap, specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME activity will assess the impact of CIU on quality of life, particularly its impact on sleep, psychological functioning, work, and activity. Current guideline approaches to the management of CIU will be evaluated, as well as treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Chair

Jonathan A. Bernstein, MD
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH

Disclosures
Royalty: CRC Press, Springer Publishing
Intellectual Property/Patent Details: University of Cincinnati
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire
Speakers Bureau: ALK, AstraZeneca, CSL Behring, Novartis, Optinose, Pharming, Sanofi, Shire
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire


Faculty

David A. Khan, MD
Professor of Medicine and Pediatrics
Allergy and Immunology Program Director
University of Texas Southwestern Medical Center
Dallas, TX

Disclosures
Royalty: Elsevier, UpToDate
Speakers Bureau: Genentech
Data Safety Monitoring Committee: Aimmune


Prof. Dr. med. Dr. hc Torsten Zuberbier
Head of the Allergy Center Charité - Dermatology Clinic
Spokesman for the Comprehensive Allergy Center Charité
Allergy Center Charité
Charité - Universitätsmedizin Berlin
Berlin, Germany

Disclosures
Consulting Fee: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Speakers Bureau: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Committee Member: WHO-Initiative "Allergic Rhinitis and its Impact on Asthma" (ARIA)
Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI)
Head: European Centre for Allergy Research Foundation (ECARF)
Secretary General: Global Allergy and Asthma European Network (GA2LEN)
Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organisation (WAO)


Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, April 18, 2019 to April 17, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Participation Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Contact Information for Questions about the Activity

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

1.00 CME
Integrity Continuing Education, Inc.
Overcoming Barriers to Initiating or Intensifying Insulin Therapy: Best Practices for the Family Physician

Overcoming Barriers to Initiating or Intensifying Insulin Therapy: Best Practices for the Family Physician

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: April 11, 2019
Expires: April 11, 2020
1.0 hour to complete

Provided By

Target Audience

This educational initiative has been designed for family practice and primary care providers (PCPs) involved in the management of patients with diabetes.

Activity Description

A BioDigital Human on-demand simulation activity has been developed as a derivative of the live program content. Simulation decisions and feedback will be supported by evidence-based content and expert faculty explanation.

Learning Objectives

Upon completion of this educational activity, participants will be able to:

  • Articulate clinical strategies for the timely initiation and modification, and intensification of insulin therapy to achieve glycemic control
  • Explain novel strategies to optimize insulin therapy in clinical practice to improve glucose control, reduce risk of weight gain and hypoglycemia, and increase patient access, acceptance and adherence
  • Utilize a patient-centered approach to individualize therapy and appropriately and effectively transition patients to insulin and insulin combinations

Statement of Educational Need

Although practitioners know poor glycemic control puts their patients at increased risk for developing diabetes complications, many delay insulin therapy. This program has been developed to aid family practice clinicians, who are at the frontline of care for these individuals. It will examine the safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) data of newer basal insulin analogs as compared to older insulins. In addition, our faculty will review clinical data on combinations of basal insulin with rapid-acting insulin and GLP-1 receptor agonists and provide updates on newer follow-on insulin therapies. The ultimate goal is to provide clinicians with the skills to provide patient-centered care in order to individualize therapy and improve patient satisfaction, adherence and quality of life (QOL).

Faculty

Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Supervisor Nurse Practitioner
Henry Ford Health System
Division of Endocrinology, Diabetes and Bone Disorders
Detroit, Michigan


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Davida F. Kruger, MSN, APN-BC, BC-ADM
Advisory Boards: Abbott, Dexcom, Eli Lilly & Company, Intarcia, Janssen, Novo Nordisk, Sanofi Aventis,
Speakers Bureau: Abbott, AstraZeneca, BI Lilly, Dexcom, Insulet, Janssen, Lilly, Novo Nordisk, Valeritas,
Grants/Research Support Committees: Abbott, AstraZeneca, Dexcom, Eli Lilly, Hemsley Foundation, Lexicom, Novo Nordisk,
Stock: Dexcom

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 11, 2019 through April 11, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi US and Novo Nordisk do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by educational grants from Sanofi US and Novo Nordisk.

1.25 CME / CNE
Vindico
Applying New Guidelines, Imaging, and Insights on Extending the Treatment Window in Acute Ischemic Stroke

Applying New Guidelines, Imaging, and Insights on Extending the Treatment Window in Acute Ischemic Stroke

Start

Activity Details

Free CME/CNE
1.25 AMA PRA Category 1 Credit(s)
1.25 contact hours
Released: April 5, 2019
Expires: April 4, 2020
1.25 hours to complete

Accredited By

This continuing education activity is provided by Vindico Medical Education.

Target Audience

The intended audience for this activity is neurologists, cardiologists, nurses, and other health care professionals involved in the treatment of patients with acute ischemic stroke.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

Physicians

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Incorporate the use of image-guided treatment to improve outcomes in patients with AIS.

Nurses

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Assess the use of image-guided treatment to improve outcomes in patients with AIS.

Activity Description

Based on the success of several new clinical trials, the American Heart Association/American Stroke Association released updated stroke treatment guidelines in 2018. The guidelines address prehospital management, diagnosis, and treatment. Key revisions include extending the treatment window for mechanical thrombectomy in eligible patients and broadening the number of patients who qualify for thrombolysis. Advances in imaging techniques and technology have improved the overall management of acute ischemic stroke (AIS), and physicians must keep apprised of how to best incorporate these findings into practice to improve patient care. This CME/CNE activity will review the revised guidelines for patients with suspected AIS and patients who present outside the recommended time limit for thrombolysis, as well as the use of image-guided treatment to improve outcomes.

Faculty

Activity Chair

Philip B. Gorelick, MD, MPH
Adjunct Professor, Davee Department of Neurology
Division of Vascular Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures
No relevant financial relationships to disclose.


Faculty

Gregory W. Albers, MD
Director, Stanford Stroke Center
Coyote Foundation Professor of Neurology and
Neurological Sciences
Stanford University Medical Center
Stanford, CA
Disclosures
Consulting Fee: Genentech, iSchemaView, Medtronic
Ownership Interest: iSchemaView


Edward C. Jauch, MD, MS
Chief of System Research
Mission Research Institute/Mission Health
Asheville, NC
Disclosures
Consulting Fee: Biogen


Christopher A. Lewandowski, MD
Executive Vice Chair, Department of Emergency Medicine
Henry Ford Health System
Clinical Professor of Emergency Medicine, Wayne State University
Detroit, MI
Disclosures
Consulting Fee: Shire
Research Funding: NIH


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Maria Gannett, MSN, CRNP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center (ANCC) Commission on Accreditation’s Standards for Commercial Support, all CME/CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME/CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education, LLC, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide 1.25 contact hours for nurses.

This enduring material is approved for 1 year from the date of original release, April 5, 2019 to April 4, 2020.

Instructions for Receiving Credit

To participate in this CME/CNE activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Learner-Paced Continuing Nursing Education Contact Hour Certificate.

MIPS Qualifying Activity

Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Contact Information for Questions about the Activity

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME/CNE Questions?
Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
Postgraduate Institute for Medicine
Clinical Convergence®: Approaching Chronic Urticaria from the Patient Perspective

Clinical Convergence®: Approaching Chronic Urticaria from the Patient Perspective

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: March 7, 2019
Expires: March 6, 2020
45 minutes to complete

Jointly Provided By

Postgraduate Institute for Medicine (PIM) in joint providership with RMEI Medical Education, LLC (RMEI).

Target Audience

US-based allergy/immunology and dermatology clinicians

Learning Objectives

After engaging in this educational activity, participants will be able to:

  1. Recognize physical exam findings and symptomatology suggestive of chronic urticaria (CU) and appropriately apply evidence-based practices regarding diagnostic testing and laboratory workup
  2. Utilize a guideline-driven approach to treatment intensification for safe and effective management of CU patients in need of second- and third-line treatment options, while taking into account quality of life issues

Activity Description

This activity is designed to engage your critical thinking and challenge suboptimal approaches to patient care. It features videos of 2 patients with CU and challenging interactive questions related to their histories and treatments. You will have an opportunity to hear the patients’ perspectives of CU and learn from our expert faculty.

Statement of Educational Need

Urticaria is an inflammatory skin condition characterized by intensely pruritic, erythematous wheals, commonly referred to as “hives,” ranging from several millimeters to several centimeters in diameter.1 Individual wheals characteristically resolve within 24 hours of development without leaving residual skin markings. However, resolving lesions are often concomitantly replaced by new wheals.

Acute urticaria tends to be self-limiting, often resolving within hours to days.2 By contrast, a diagnosis of chronic urticaria (CU), also referred to as chronic idiopathic urticaria (CIU) or chronic spontaneous urticaria (CSU), is made when symptoms last >6 weeks.3 In some cases of CU, symptoms persist continually, while others are episodic with symptoms occurring at varying intervals (hours to weeks).4 Approximately 40% of patients with CU also develop angioedema,5 characterized by rapid swelling of the lower layers of the dermis and the subcutaneous or submucosal tissue of the skin and mucous membranes, most commonly affecting the lips and eyelids, or more rarely, the respiratory or gastrointestinal tracts.6 The point prevalence of CU is estimated at 0.5% to 1%.4

References:

  1. World Allergy Organization. Urticaria and angioedema: synopsis. 2004. www.worldallergy.org/professional/allergic_diseases_center/urticaria/urticariasynopsis.php. Accessed January 18, 2019.
  2. Axelrod S, Davis-Lorton M. Urticaria and angioedema. Mt Sinai J Med. 2011;78(5):784-802.
  3. Greaves M. Chronic urticaria. J Allergy Clin Immunol. 2000;105(4):664-672.
  4. Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37(5):631-650.
  5. Amar SM, Dreskin SC. Urticaria. Prim Care. 2008;35(1):141-157.
  6. Maurer M, Weller K, Bindsley-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317-330.

Faculty

Michael E. Manning, MD, FAAAAI, FACAAI
President/Medical Director
Medical Research of Arizona
Allergy, Asthma and Immunology Associates, Ltd
Scottsdale, AZ

Michael E. Manning, MD, FAAAAI, FACAAI, is president of Allergy, Asthma and Immunology Associates, Ltd., and medical director of the clinical research division, Medical Research of Arizona. Dr Manning received his medical degree from the University of Texas Medical School at Houston. He completed an internship and subsequently residency in internal medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ, and an allergy and immunology fellowship at Scripps Clinic and Research Foundation in La Jolla, CA.

Dr Manning has served as president of the Greater Phoenix Allergy Society, the Arizona State Allergy and Asthma Society, and the Western Society of Allergy, Asthma and Immunology. He is a fellow of the American College of Allergy, Asthma and Immunology and American Academy of Allergy, Asthma and Immunology. Dr Manning is currently on the Board of Regents of the American College of Allergy, Asthma and Immunology.

Michael E. Manning, MD, FAAAAI, FACAAI, has affiliations with CSL Behring, DBV Technologies, Pharming, Shire (Consulting Fees); AstraZeneca, CSL Behring, Genentech, Pharming, Shire (Speakers Bureaus); Aimmune, BioCryst, CSL Behring, Genentech/Novartis, GSK, Hoffmann-La Roach, Merck, Sanofi, Shire/Dyax (Contracted Research).


Anne Marie Ditto, MD
Associate Professor of Medicine
Division of Allergy-Immunology  
Northwestern University  
Feinberg School of Medicine  
Chicago, IL 

Anne Marie Ditto, MD, is an associate professor of medicine in the division of Allergy-Immunology at Northwestern University Feinberg School of Medicine in Chicago, IL. She earned her medical degree at the University of Illinois at Chicago. Her internship, residency, and fellowship were all completed at Northwestern University. Dr Ditto is board certified in allergy-immunology.

Dr Ditto is a practicing allergist with a special interest in urticaria, eosinophilic esophagitis, asthma, and idiopathic anaphylaxis. She volunteers monthly at the Community Health Clinic where she founded an asthma/allergy clinic. She is also actively involved in the allergy-immunology training program at Northwestern, where she has trained over 75 allergists and teaches students and residents in outpatient clinics.

Dr Ditto was invited to fellowship in the American College of Physicians (ACP) and Royal Society of Medicine (RSM) and her distinguished teaching and volunteer work has been recognized through numerous awards, including the Northwestern Medical Faculty Foundation “Center of Excellence Award” for Community Service and Community Health’s “Volunteer Specialist of the Year”.

Dr Ditto is a former president of the Illinois Society of Allergy, Asthma and Immunology and currently serves as Governor of the Midwest Region of the American Academy of Allergy, Asthma and Immunology’s Federation of Regional State and Local Allergy, Asthma and Immunology Societies (RSLAAIS) and also serves as vice-chair of the AAAAI anaphylaxis committee. She has published numerous articles and book chapters in the field of allergy-immunology and recently edited the “Anaphylaxis” issue of Immunology and Allergy Clinics of North America.

Anne M. Ditto, MD, has no affiliations with commercial interests to disclose.


Conflict of Interest Policy/Disclosure Statement

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The PIM planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose.

The patients have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Media

Internet

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please e-mail information@pimed.com.

Complete the evaluation form and participants will be entered into a drawing to win a $100 Amazon Gift Card!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
Global Education Group
ADPKD - What Your Patients Want You to Know

ADPKD - What Your Patients Want You to Know

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: December 31, 2018
Expires: December 31, 2019
30 minutes to complete

Jointly Provided By

In Partnership With

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Terms of Offering

This activity was released on 12/31/18 and is valid for one year. Requests for credit must be made no later than 12/31/19.

Target Audience

The educational design of this activity addresses the needs of nephrology and primacy care HCPs involved in the treatment of patients with ADPKD.

Statement of Need/Program Overview

Autosomal dominant polycystic kidney disease (ADPKD) is a chronic inherited progressive condition in which renal cysts develop and expand, eventually leading to severe loss of kidney function. Complications include pain, hypertension, and cardiovascular disease. Unless patients undergo dialysis or transplantation, ADPKD is inevitably fatal. Because it is a genetically transmitted disease, there is a 50/50 chance that each child of a parent with ADPKD will develop the disease. Management of ADPKD has evolved significantly in recent years; in 2018, the first drug indicated for slowing progression of the disease was approved.

ADPKD is considered a rare disease, but with a prevalence of approximately 1:1000, the odds are high that most primary care practices have 1 or more patients with the condition – whether or not it has been diagnosed. Primary care providers would benefit from education that raises their awareness of ADPKD, explains strategies for managing the disease and its complications, and provides them with tools to promote and preserve optimal patient health for as long as possible.

This unique online Clinical Comparison CME/CE activity allows learners to learn about ADPKD, discover evidence-based treatment strategies, apply their learning in a series of interactive real-world challenges, receive feedback on their choices, and compare their choices with those of their peers. The content of the program was developed, in part, through interviews with ADPKD patients and their caregivers, who shared their insights and what they wish their clinicians knew about the disease, its management, and its impact on their lives.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Identify clinical approaches for the early recognition, efficient evaluation, and timely diagnosis of autosomal dominant polycystic kidney disease (ADPKD)
  • Identify data-driven approaches to the comprehensive care of patients with ADPKD
  • Recognize which patients with ADPKD are most likely to benefit from currently available and emerging therapies for ADPKD

Faculty

Brittany P. Cavanaugh, DO
Professor of Internal Medicine
Yale University School of Medicine
New Haven, Connecticut


Neera Dahl, MD
Associate Professor of Nephrology
Yale University School of Medicine
New Haven, Connecticut


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Global Academy for Medical Education. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time.

System Requirements

PC
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader

MAC
MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Safari
Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Brittany P. Cavanaugh, DO
Nothing to disclose

Neera Dahl, MD
Has been a Consultant/Independent Contractor and a member of the Speakers’ Bureau for Otsuka America Pharmaceutical, Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Tom Garry: Nothing to disclose
Shirley V. Jones, MBA: Nothing to disclose
Mike LoPresti: Nothing to disclose
Ron Schaumburg: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Global Academy for Medical Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Copyright © 2018 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc. and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, the accredited provider or the Publisher will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

0.75 CME
Integrity Continuing Education, Inc.
Strategies to Provide Individualized Treatment in Moderate-to-Severe Atopic Dermatitis

Strategies to Provide Individualized Treatment in Moderate-to-Severe Atopic Dermatitis

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: December 7, 2018
Expires: December 7, 2019
45 minutes to complete

Provided By

Target Audience

This educational initiative has been designed for dermatologists, allergists, primary care physicians, nurse practitioners, and physician assistants involved in the management of atopic dermatitis (AD).

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Utilize updated criteria and guidelines to accurately diagnose AD and assess severity
  • Describe the limitations of currently available therapies in addressing underlying AD pathophysiology
  • Evaluate recent clinical evidence on the utility of approved and emerging biologic agents to address the underlying pathophysiology of AD
  • Discuss strategies that will improve patient satisfaction with treatment and reduce the burden of comorbidities

Activity Description

Patients with atopic dermatitis (AD) are sub-optimally managed in current clinical practice and hence report a poor quality of life and high burden from their disease and comorbidities. There remains an unmet need for effective therapies that not only relieve distressing symptoms of AD, but also improve long-term outcomes for patients. An improved understanding of the pathogenesis of AD has led to the development of biologic agents, including dupilumab, which are known to target the underlying pathophysiology of AD. Despite this progress, AD continues to impose a huge healthcare burden due to knowledge and competence deficits among healthcare professionals.

There is a need to improve the diagnosis, assessment of severity, treatment, and management of AD to enable improved outcomes and quality of life among patients. This program will include topics that will improve healthcare professionals’ ability to accurately diagnose and recognize AD among patients presenting with eczema by informing participants about updated diagnostic criteria and assessment scores to differentially diagnose AD and its severity. Discussions on updated guidelines, recommendations, and recent clinical evidence to inform treatment decisions to alleviate the symptom burden of AD will be included and evaluated. Clinicians will also learn strategies to improve communication and adherence to treatment, and address the comorbidities of AD.

Faculty

Amy S. Paller, MS, MD
Chair, Department of Dermatology
Director, Northwestern University Skin Disease Research Center
Walter J. Hamlin Professor of Dermatology
Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois


Jonathan M. Spergel, MD, PhD
Professor of Pediatrics
Chief, Allergy Section
Stuart E. Starr Endowed Chair of Pediatrics
Director, Center for Pediatric Eosinophilic Disease
Director, FARE Center of Excellence
The Children’s Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Amy S. Paller, MS, MD
Consulting Fees: AbbVie, Asana, Dermavant, Dermira, Galderma, Eli Lilly, Forte, Leo, Matrisys, Menlo, Morphosys/Galapagos, Novartis Pharmaceuticals Corporation, Pfizer, Promius, Sanofi Genzyme and Regeneron Pharmaceuticals
Contracted Research: AbbVie, Anaptysbio, Eli Lilly, Galderma, Incyte, Leo, Janssen, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals

Jonathan M. Spergel, MD, PhD
Royalty: Up-To-Date
Consulting Fees: Regeneron Pharmaceuticals, Shire
Contracted Research: AbbVie, Regeneron Pharmaceuticals

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of December 7, 2018 through December 7, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions about the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

0.75 CME
Postgraduate Institute for Medicine
Clinical Reflections®: Reflecting on Errors and Missed Opportunities in Chronic Urticaria

Clinical Reflections®: Reflecting on Errors and Missed Opportunities in Chronic Urticaria

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: February 1, 2019
Expires: January 31, 2020
45 minutes to complete

Jointly Provided By

Postgraduate Institute for Medicine (PIM) in joint providership with RMEI Medical Education (RMEI).

Target Audience

US-based allergy/immunology and dermatology clinicians

Learning Objectives

After engaging in this educational activity, participants will be able to:

  1. Recognize physical exam findings and symptomatology suggestive of chronic urticaria (CU) and appropriately apply evidence-based practices regarding diagnostic testing and laboratory workup
  2. Utilize a guideline-driven approach to treatment intensification for safe and effective management of CU patients in need of second- and third-line treatment options, while taking into account quality of life issues

Activity Description

This unique educational initiative harnesses the power of reflection and recognition of suboptimal approaches to patient care to allow you to rethink clinical decisions based on the scenarios presented, and to modify treatment plans accordingly. You can compare your responses to interactive questions with those of your peers and learn from our expert faculty.

Statement of Educational Need

Urticaria is an inflammatory skin condition characterized by intensely pruritic, erythematous wheals, commonly referred to as “hives,” ranging from several millimeters to several centimeters in diameter.1 Individual wheals characteristically resolve within 24 hours of development without leaving residual skin markings. However, resolving lesions are often concomitantly replaced by new wheals.

Acute urticaria tends to be self-limiting, often resolving within hours to days.2 By contrast, a diagnosis of chronic urticaria (CU), also referred to as chronic idiopathic urticaria (CIU) or chronic spontaneous urticaria (CSU), is made when symptoms last >6 weeks.3 In some cases of CU, symptoms persist continually, while others are episodic with symptoms occurring at varying intervals (hours to weeks).4 Approximately 40% of patients with CU also develop angioedema,5 characterized by rapid swelling of the lower layers of the dermis and the subcutaneous or submucosal tissue of the skin and mucous membranes, most commonly affecting the lips and eyelids, or more rarely, the respiratory or gastrointestinal tracts.6 The point prevalence of CU is estimated at 0.5% to 1%.4

References:
  1. World Allergy Organization. Urticaria and angioedema: synopsis. 2004. www.worldallergy.org/professional/allergic_diseases_center/urticaria/urticariasynopsis.php. Accessed December 21, 2018.
  2. Axelrod S, Davis-Lorton M. Urticaria and angioedema. Mt Sinai J Med. 2011;78(5):784-802.
  3. Greaves M. Chronic urticaria. J Allergy Clin Immunol. 2000;105(4):664-672.
  4. Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37(5):631-650.
  5. Amar SM, Dreskin SC. Urticaria. Prim Care. 2008;35(1):141-157.
  6. Maurer M, Weller K, Bindsley-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317-330.

Faculty

Michael E. Manning, MD, FAAAAI, FACAAI
Michael E. Manning, MD, FAAAAI, FACAAI
President/Medical Director
Medical Research of Arizona
Allergy, Asthma and Immunology Associates, Ltd.
Scottsdale, AZ

Michael E. Manning, MD, FAAAAI, FACAAI, is president of Allergy, Asthma and Immunology Associates, Ltd., and medical director of the clinical research division, Medical Research of Arizona.

Dr Manning is a graduate of Baylor University in Waco, TX and he received his medical degree from the University of Texas Medical School at Houston. He completed an internship and subsequently residency in internal medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ, and an allergy and immunology fellowship at Scripps Clinic and Research Foundation in La Jolla, CA.

Dr Manning has served as president of the Greater Phoenix Allergy Society, the Arizona State Allergy and Asthma Society, and the Western Society of Allergy, Asthma and Immunology. He is a fellow of the American College of Allergy, Asthma and Immunology and American Academy of Allergy, Asthma and Immunology. Dr Manning is currently on the Board of Regents of the American College of Allergy, Asthma and Immunology.

Michael E. Manning, MD, FAAAAI, FACAAI, has affiliations with CSL Behring, DBV Technologies, Pharming, Shire (Consulting Fees); AstraZeneca, CSL Behring, Genentech, Pharming, Shire (Speakers Bureaus); Aimmune, BioCryst, CSL Behring, Genentech/Novartis, GSK, Hoffmann-La Roach, Merck, Sanofi, Shire/Dyax (Contracted Research).



Anne Marie Ditto, MD 
Associate Professor of Medicine
Division of Allergy-Immunology 
Northwestern University
Feinberg School of Medicine 
Chicago, IL 

Anne Marie Ditto, MD, is an associate professor of medicine in the division of Allergy-Immunology at Northwestern University Feinberg School of Medicine in Chicago, IL. She earned her medical degree at the University of Illinois at Chicago. Her internship, residency, and fellowship were all completed at Northwestern University. Dr Ditto is board certified in allergy-immunology.

Dr Ditto is a practicing allergist with a special interest in urticaria, eosinophilic esophagitis, asthma, and idiopathic anaphylaxis. She volunteers monthly at the Community Health Clinic where she founded an asthma/allergy clinic. She is also actively involved in the allergy-immunology training program at Northwestern, where she has trained over 75 allergists and teaches students and residents in outpatient clinics.

Dr Ditto was invited to fellowship in the American College of Physicians (ACP) and Royal Society of Medicine (RSM) and her distinguished teaching and volunteer work has been recognized through numerous awards, including the Northwestern Medical Faculty Foundation “Center of Excellence Award” for Community Service and Community Health’s “Volunteer Specialist of the Year.

Dr Ditto is a former president of the Illinois Society of Allergy, Asthma and Immunology and currently serves as Governor of the Midwest Region of the American Academy of Allergy, Asthma and Immunology’s Federation of Regional State and Local Allergy, Asthma and Immunology Societies (RSLAAIS) and also serves as vice-chair of the AAAAI anaphylaxis committee. She has published numerous articles and book chapters in the field of allergy- immunology and recently edited the “Anaphylaxis” issue of Immunology and Allergy Clinics of North America.

Anne Marie Ditto, MD, has no affiliations with commercial interests to disclose.



Luz Fonacier, MD, FAAAAI, FACAAI
Professor of Medicine
State University of New York at Stony Brook
Stony Brook, NY
Head of Allergy
Program Director, Allergy and Immunology
Fellowship Program
NYU Winthrop Hospital
Mineola, NY 

Luz Fonacier, MD, FAAAAI, FACAAI, is the head of allergy in NYU Winthrop Hospital, a clinical campus of Stony Brook University School of Medicine and serves as the program director for the Allergy and Immunology Fellowship Program. Dr Fonacier is also a professor of medicine in USNY at Stony Brook. She completed residencies in dermatology and internal medicine, a fellowship in allergy and immunology in New York Hospital-Cornell Medical Center, and a fellowship in dermal immunology at New York University Medical Center.

Dr Fonacier serves as the Treasurer of the American College of Allergy, Asthma and Immunology (ACAAI). She chaired the Committee on Dermatologic Allery of the ACAAI and the Food Allergy, Dermatologic, Drug and Anaphylaxis Interest Section of the American Academy of Allergy, Asthma and Immunology (AAAAI). She is the recipient of the ARTrust™  and Anjuli Seth Nayak AAAAI Lectureship, the ACAAI John P. McGovern Lectureship, the ACAAI Jean A. Chapman Memorial Lectureship, the ACAAI “Women in Allergy Award”, and the Presidential Award of Asian Pacific Association of Allergy and Clinical Immunology. Dr Fonacier also served as president of the Long Island Allergy Society.

Dr Fonacier has numerous publications in textbooks and journals and continues to be a speaker and faculty in the annual national conventions of ACAAI, AAAAI, and other national and international societies. Because of her training in dermatology, allergy, and immunology, Dr Fonacier’s special interest is the dermatologic manifestations of allergic diseases.

Luz Fonacier, MD, FAAAAI, FACAAI, has affiliations with Regeneron (Consulting Fees); Regeneron (Speakers Bureaus); Pfizer, Regeneron, Shire (Contracted Research).



Conflict of Interest Policy/Disclosure Statement

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

Complete the evaluation form and participants will be entered into a drawing to win a $100 Amazon Gift Card!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.50 CME
Global Education Group
The Changing Landscape of IBD: Emerging Concepts in Patient Management

The Changing Landscape of IBD: Emerging Concepts in Patient Management

Start

A Multimedia Educational eHealth Source™

Activity Details

Free CME
1.5 AMA PRA Category 1 Credits
Released: January 17, 2019
Expires: January 17, 2020
1 hour, 30 mins to complete

Jointly Provided by

Target Audience

This activity is intended for clinical gastroenterologists and specialist NP/PAs involved in the treatment of patients with inflammatory bowel disease (IBD).

Learning Objectives

  • Evaluate disease risk and identify individuals who are likely to benefit from biologic or targeted synthetic therapy
  • Tailor management regimens for patients with inflammatory bowel disease (IBD) using a treat-to-target approach that reflects disease severity, treatment goals, therapeutic responses, and patient preferences
  • Partner with patients to provide IBD disease state education, promote shared clinical decision-making, encourage self-management efforts, and personalize long-term care
  • Discuss the cytokine networks underlying IBD pathophysiology, with a focus on newer mechanisms of action
  • Review mechanisms of current and novel non–tumor necrosis factor biologic and targeted synthetic therapies for the treatment of IBD

Activity Description

This activity presents an in-depth review of IBD patient care in moderate to severe disease, including immunopathogenesis of IBD, existing management options, shared decision-making, and investigational targeted therapies, via text and concise video commentaries provided by noted IBD experts

Statement of Educational Need

In the past 2 decades, the introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of the inflammatory bowel diseases (IBDs)—ulcerative colitis and Crohn’s disease. Current biologic therapy with tumor necrosis factor inhibitors and anti-integrins has improved the treatment of IBD flares and maintenance of clinical remission. These agents are, however, limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the pathogenesis and treatment of IBD are complex and variable, there is a need to better understand the underlying pathogenic mechanisms and develop drug therapies to target these mechanisms.1

Geared to the needs of gastroenterologists, this IBD eHealth program includes an update on patient assessment and treat-to-target goals, as well as a review of best practices in shared decision-making in treatment decisions for induction and maintenance of remission. In addition, the immunopathogenesis of IBD is discussed in the context of current and emerging targeted therapies for moderate to severe disease.

Reference

1. Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127-142.

Agenda

  • Chapter 1: Assessment Strategies and Treatment Goals in IBD
  • Chapter 2: Best Practices in Tailoring Treatment of Moderate and Severe IBD
  • Chapter 3: Evolving Concepts in IBD Pathophysiology
  • Chapter 4: Targeted Mechanism-Based Therapies for IBD on the Horizon

Faculty

Raymond K. Cross, MD, MS
Professor of Medicine
Director, Inflammatory Bowel Disease Program
University of Maryland School of Medicine
Co-Director, Digestive Health Center
University of Maryland Medical Center
Baltimore, MD


Gary R. Lichtenstein, MD
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Raymond K. Cross, MD, MS
  • Consultant/Independent Contractor: AbbVie Inc, Janssen, LabCorp, Pfizer, UCB
  • Grant/Research Support: AbbVie Inc

Gary R. Lichtenstein, MD
  • Consultant: AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Luitpold Pharmaceuticals, Inc., Merck & Co., Pfizer Inc., Prometheus Laboratories Inc., Romark, L.C., Salix Pharmaceuticals, Inc., Shire Plc, Takeda Pharmaceuticals North America, Inc., UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Grant/Research Support: Celgene Corporation, Janssen Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Shire Plc, UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastroenterology and Hepatology (Gastro-Hep Communications, Inc.), Luitpold Pharmaceuticals, Inc., McMahon Publishing, Merck & Co., Romark, L.C., Springer Science+Business Media, UpToDate®
  • Other/Royalty: Eli Lilly and Company (Data and Safety Monitoring Board), Janssen Pharmaceuticals, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), Pfizer Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), SLACK, Incorporated (Book Royalty), Takeda Pharmaceuticals North America, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania)

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Lindsay Borvansky, Andrea Funk, Liddy Knight, Kayla Messer, Jim Kappler, PhD, Julia Muino.

Designation of Credit

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the post-test and program evaluation. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
American Gastroenterological Association
Optimizing Management in IBD: Challenging Cases

Optimizing Management in IBD: Challenging Cases

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: December 26, 2018
Expires: December 25, 2019
0.75 hour to complete

Accredited By

The American Gastroenterological Association (AGA) Institute

Target Audience

Gastroenterologists and gastroenterology NPs and PAs

Learning Objectives

  • Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
  • Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity
  • Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
  • Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making

Faculty

Gil Y. Melmed, MD, MS (Chair)
Co-Director, Clinical Inflammatory Bowel Disease
Division of Gastroenterology/Department of Medicine
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA


Adam S. Cheifetz, MD
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA


Gary R. Lichtenstein, MD, FACP, FACG, AGAF
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA

Disclosure of Conflicts of Interest

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda (Consulting Fees); Pfizer (Research).
  • Adam S. Cheifetz, MD, has affiliations with AbbVie, Arena, Ferring, Janssen, Pfizer, Samsung, Takeda (Consulting Fees); Miraca (Grant/Research Support).
  • Gary R. Lichtenstein, MD, FACP, FACG, AGAF, has affiliations with Abbott Corporation/AbbVie, Celgene, CellCeutrix, Ferring, Gilead, Janssen Orthobiotech, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals, Shire, Takeda, UCB (Consulting Fees); Celgene, Janssen Orthobiotech, Salix Pharmaceuticals, Shire, UCB (Research); Luitpold/American Regent, Merck, Romark (Other Financial Benefit).  

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

AGA Institute

  • Monique Dyson, has no affiliations with commercial interests to disclose.
  • Sandra Amos, has no affiliations with commercial interests to disclose.

Physician Continuing Medical Education

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. After the successful completion of A Pathway to Evidence-Based Management of IBD and Optimizing Management in IBD: Challenging Cases, learners will receive an AGA-branded certificate recognizing their mastery of IBD management.



COMPLETE THE EVALUATION FORM AND GET A CHANCE TO WIN A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.
 
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.


Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Pages